{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:59:50Z","timestamp":1790380790424,"version":"4.1.0"},"reference-count":72,"publisher":"Georg Thieme Verlag KG","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bayer AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"abstract":"<jats:p>Ischemic stroke is increasing in frequency and results in significant morbidity and mortality. Disability due to ischemic stroke results from motor, language, and cognitive deficits, with depression and nonmotor symptoms increasingly recognized as common and associated with disability and a reduced quality of life. Stroke associated with major cardiac sources makes up about one-fifth of all strokes, with the remainder being noncardioembolic. Most noncardioembolic strokes fall into three subtypes: large artery atherosclerosis, small vessel disease, and cryptogenic. Thrombosis and thromboembolism underlie most stroke subtypes, and antithrombotic therapy remains an essential component of secondary stroke prevention. Survivors of ischemic stroke have a considerable risk of disabling recurrent stroke and other major ischemic events despite advances in prevention strategies. Dual antiplatelet therapy is the standard secondary prevention strategy for short-term treatment after minor stroke or transient ischemic attack, and aspirin monotherapy is used for more severe stroke and long-term thromboprophylaxis. Current antiplatelet strategies are limited by moderate efficacy and bleeding risk. Inhibition of activated factor XI (FXIa) in the intrinsic pathway of the coagulation cascade has the potential to prevent recurrent stroke by attenuating pathologic thrombosis with minimal effects on hemostasis. The first efficacy trial of FXIa inhibition for stroke prevention has been completed and shows a reduction in ischemic stroke without an increase in major hemorrhage.<\/jats:p>","DOI":"10.1055\/a-2952-7857","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:58:52Z","timestamp":1788994732000},"source":"Crossref","is-referenced-by-count":0,"title":["Antithrombotic Therapy for Secondary Prevention After Noncardioembolic Ischemic Stroke: Current Status, Limitations, and Future Directions"],"prefix":"10.1055","author":[{"given":"Mukul","family":"Sharma","sequence":"additional","affiliation":[{"name":"McMaster University, Ontario, Canada","place":["Hamilton"],"department":["Department of Medicine (Neurology) and Population Health Research Institute"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[{"name":"McMaster University, Ontario, Canada","place":["Hamilton"],"department":["Department of Medicine and Thrombosis and Atherosclerosis Research Institute"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashkan","family":"Shoamanesh","sequence":"additional","affiliation":[{"name":"McMaster University, Ontario, Canada","place":["Hamilton"],"department":["Department of Medicine (Neurology) and Population Health Research Institute"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Claiborne","family":"Johnston","sequence":"additional","affiliation":[{"name":"Corporate Headquarters, Texas, United States","place":["Austin"],"department":["Harbor Health"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme J.","family":"Hankey","sequence":"additional","affiliation":[{"name":"Medical School, The University of Western Australia, Western Australia, Australia","place":["Perth"],"department":["Centre for Neuromuscular and Neurological Disorders"]},{"name":"Perron Institute for Neurological and Translational Science, Western Australia, Australia","place":["Perth"],"department":["Stroke Research Centre"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1474-4422(24)00369-7","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"23","author":"GBD 2021 Stroke Risk Factor Collaborators","year":"2024","journal-title":"Lancet Neurol"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/17474930241308142","article-title":"World Stroke Organization: global stroke fact sheet 2025","volume":"20","author":"V L Feigin","year":"2025","journal-title":"Int J Stroke"},{"issue":"12","key":"ref3","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S1474-4422(23)00277-6","article-title":"Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization-Lancet Neurology Commission","volume":"22","author":"V L Feigin","year":"2023","journal-title":"Lancet Neurol"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/CIRCULATIONAHA.124.070541","article-title":"Arterial thrombosis: present and future","volume":"150","author":"J I Weitz","year":"2024","journal-title":"Circulation"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1474-4422(22)00302-7","article-title":"Risk of subsequent disabling or fatal stroke in patients with transient ischaemic attack or minor ischaemic stroke: an international, prospective cohort study","volume":"21","author":"C Hobeanu","year":"2022","journal-title":"Lancet Neurol"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1016\/S2214-109X(20)30069-3","article-title":"Mortality and recurrent vascular events after first incident stroke: a 9-year community-based study of 0.5 million Chinese adults","volume":"8","author":"Y Chen","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"D O Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"03","key":"ref8","doi-asserted-by":"crossref","first-page":"I","DOI":"10.1177\/23969873221100032","article-title":"European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack","volume":"7","author":"J Dawson","year":"2022","journal-title":"Eur Stroke J"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"CLXIII","DOI":"10.1177\/2396987321992905","article-title":"European Stroke Organisation (ESO) guidelines on management of transient ischaemic attack","volume":"6","author":"A C Fonseca","year":"2021","journal-title":"Eur Stroke J"},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1161\/CIRCULATIONAHA.124.069651","article-title":"Comparison of American and European guideline recommendations for diagnostic workup and secondary prevention of ischemic stroke and transient ischemic attack","volume":"150","author":"M JHL Mulder","year":"2024","journal-title":"Circulation"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"J A Joglar","year":"2024","journal-title":"Circulation"},{"issue":"04","key":"ref12","first-page":"CD003242","article-title":"Anticoagulants versus antiplatelet agents for acute ischaemic stroke","volume":"2002","author":"E Berge","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"issue":"09","key":"ref13","first-page":"CD001342","article-title":"Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin","volume":"2012","author":"E L De Schryver","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"02","key":"ref14","first-page":"CD000248","article-title":"Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack","volume":"2009","author":"P A Sandercock","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"14","key":"ref15","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"J W Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"issue":"07","key":"ref16","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.jtha.2023.04.021","article-title":"News at XI: moving beyond factor Xa inhibitors","volume":"21","author":"J C Fredenburgh","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref17","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1474-4422(13)70310-7","article-title":"Embolic strokes of undetermined source: the case for a new clinical construct","volume":"13","author":"R G Hart","year":"2014","journal-title":"Lancet Neurol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1212\/WNL.62.8_suppl_6.S7","article-title":"Risk factors for TIA and TIA as a risk factor for stroke","volume":"62","author":"R L Sacco","year":"2004","journal-title":"Neurology"},{"issue":"08","key":"ref19","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.28.8.754","article-title":"The Harvard Cooperative Stroke Registry: a prospective registry","volume":"28","author":"J P Mohr","year":"1978","journal-title":"Neurology"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/hs1101.098524","article-title":"Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank","volume":"32","author":"A J Grau","year":"2001","journal-title":"Stroke"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1161\/STROKEAHA.115.011164","article-title":"Lipids and cerebrovascular disease: research and practice","volume":"46","author":"S Yaghi","year":"2015","journal-title":"Stroke"},{"key":"ref22","first-page":"9589831","article-title":"TOAST subtypes of ischemic stroke and its risk factors: a hospital-based study at CIPTO Mangunkusumo Hospital, Indonesia","volume":"2018","author":"S Harris","year":"2018","journal-title":"Stroke Res Treat"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/rth2.12080","article-title":"The coagulation system in atherothrombosis: implications for new therapeutic strategies","volume":"2","author":"R H Olie","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41583-024-00892-0","article-title":"Endothelial cells as key players in cerebral small vessel disease","volume":"26","author":"R Kremer","year":"2025","journal-title":"Nat Rev Neurosci"},{"issue":"09","key":"ref25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11910-019-0979-y","article-title":"Antiplatelet therapy in cerebral small vessel disease","volume":"19","author":"D S Bouasquevisque","year":"2019","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"09","key":"ref26","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1161\/STROKEAHA.123.043626","article-title":"Is there still a role for dual antiplatelet therapy in the secondary prevention of lacunar stroke?","volume":"54","author":"A Shoamanesh","year":"2023","journal-title":"Stroke"},{"issue":"23","key":"ref27","doi-asserted-by":"crossref","first-page":"e2561","DOI":"10.1212\/WNL.0000000000201293","article-title":"MRI-visible perivascular spaces and risk of incident dementia: the Framingham Heart Study","volume":"99","author":"J R Romero","year":"2022","journal-title":"Neurology"},{"issue":"24","key":"ref28","doi-asserted-by":"crossref","first-page":"e026601","DOI":"10.1161\/JAHA.122.026601","article-title":"Brain enlarged perivascular spaces as imaging biomarkers of cerebrovascular disease: a clinical narrative review","volume":"11","author":"S Ramaswamy","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"21","key":"ref29","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1056\/NEJMcp1503946","article-title":"Clinical practice. Cryptogenic stroke","volume":"374","author":"J L Saver","year":"2016","journal-title":"N Engl J Med"},{"issue":"08","key":"ref30","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41582-022-00663-4","article-title":"Review and update of the concept of embolic stroke of undetermined source","volume":"18","author":"H C Diener","year":"2022","journal-title":"Nat Rev Neurol"},{"issue":"15","key":"ref31","doi-asserted-by":"crossref","first-page":"e012858","DOI":"10.1161\/JAHA.119.012858","article-title":"Prevalence and overlap of potential embolic sources in patients with embolic stroke of undetermined source","volume":"8","author":"G Ntaios","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"02","key":"ref32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/23969873231168367","article-title":"The contribution of competing mechanisms in stroke despite anticoagulation in patients with atrial fibrillation","volume":"8","author":"R Herlekar","year":"2023","journal-title":"Eur Stroke J"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000352050","article-title":"The ASCOD phenotyping of ischemic stroke (updated ASCO phenotyping)","volume":"36","author":"P Amarenco","year":"2013","journal-title":"Cerebrovasc Dis"},{"issue":"09","key":"ref34","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1161\/STROKEAHA.113.001363","article-title":"Overlap of diseases underlying ischemic stroke: the ASCOD phenotyping","volume":"44","author":"G Sirimarco","year":"2013","journal-title":"Stroke"},{"issue":"09","key":"ref35","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ajpath.2024.05.010","article-title":"Platelets in thrombosis and atherosclerosis: a double-edged sword","volume":"194","author":"G Martinez Bravo","year":"2024","journal-title":"Am J Pathol"},{"issue":"9479","key":"ref36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)66702-5","article-title":"A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack","volume":"366","author":"P M Rothwell","year":"2005","journal-title":"Lancet"},{"issue":"07","key":"ref37","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1161\/STR.0b013e318296aeca","article-title":"An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"44","author":"R L Sacco","year":"2013","journal-title":"Stroke"},{"issue":"16","key":"ref38","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1056\/NEJMoa1412981","article-title":"One-year risk of stroke after transient ischemic attack or minor stroke","volume":"374","author":"P Amarenco","year":"2016","journal-title":"N Engl J Med"},{"issue":"09","key":"ref39","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1161\/CIRCULATIONAHA.118.035864","article-title":"Stroke outcomes in the COMPASS trial","volume":"139","author":"M Sharma","year":"2019","journal-title":"Circulation"},{"issue":"04","key":"ref40","doi-asserted-by":"crossref","first-page":"e022638","DOI":"10.1161\/JAHA.121.022638","article-title":"Ischemic stroke severity and mortality in patients with and without atrial fibrillation","volume":"11","author":"N E Vinding","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"24","key":"ref41","first-page":"e2257","article-title":"Profile of and risk factors for poststroke cognitive impairment in diverse ethnoregional groups","volume":"93","author":"J W Lo","year":"2019","journal-title":"Neurology"},{"issue":"03","key":"ref42","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1474-4422(18)30442-3","article-title":"Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford Vascular Study","volume":"18","author":"S T Pendlebury","year":"2019","journal-title":"Lancet Neurol"},{"issue":"02","key":"ref43","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1136\/jnnp.57.2.202","article-title":"Cognitive impairment after stroke: frequency, patterns, and relationship to functional abilities","volume":"57","author":"T K Tatemichi","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"04","key":"ref44","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1046\/j.1532-5415.2002.50165.x","article-title":"Cognitive impairment after stroke: clinical determinants and its associations with long-term stroke outcomes","volume":"50","author":"M D Patel","year":"2002","journal-title":"J Am Geriatr Soc"},{"issue":"04","key":"ref45","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000107102","article-title":"The combined effect of age, education, and stroke on dementia and cognitive impairment no dementia in the elderly","volume":"24","author":"D De Ronchi","year":"2007","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"08","key":"ref46","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/ijs.12357","article-title":"Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies","volume":"9","author":"M L Hackett","year":"2014","journal-title":"Int J Stroke"},{"issue":"08","key":"ref47","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/ijs.12356","article-title":"Part II: predictors of depression after stroke and impact of depression on stroke outcome: an updated systematic review of observational studies","volume":"9","author":"M A Kutlubaev","year":"2014","journal-title":"Int J Stroke"},{"issue":"02","key":"ref48","doi-asserted-by":"crossref","first-page":"e2457447","DOI":"10.1001\/jamanetworkopen.2024.57447","article-title":"Prevalence, trajectory, and factors associated with patient-reported nonmotor outcomes after stroke: a systematic review and meta-analysis","volume":"8","author":"H Ozkan","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"01","key":"ref49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Y Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"03","key":"ref50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA","volume":"379","author":"S C Johnston","year":"2018","journal-title":"N Engl J Med"},{"issue":"27","key":"ref51","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1056\/NEJMoa2111749","article-title":"Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA","volume":"385","author":"Y Wang","year":"2021","journal-title":"N Engl J Med"},{"issue":"03","key":"ref52","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA","volume":"383","author":"S C Johnston","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"ref53","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"D L Bhatt","year":"2006","journal-title":"N Engl J Med"},{"issue":"9431","key":"ref54","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"H C Diener","year":"2004","journal-title":"Lancet"},{"issue":"09","key":"ref55","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1056\/NEJMoa1204133","article-title":"Effects of clopidogrel added to aspirin in patients with recent lacunar stroke","volume":"367","author":"O R Benavente","year":"2012","journal-title":"N Engl J Med"},{"issue":"7329","key":"ref56","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists' Collaboration","year":"2002","journal-title":"BMJ"},{"issue":"02","key":"ref57","doi-asserted-by":"crossref","first-page":"CLXXXVIII","DOI":"10.1177\/23969873211000877","article-title":"European Stroke Organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA","volume":"6","author":"J Dawson","year":"2021","journal-title":"Eur Stroke J"},{"issue":"03","key":"ref58","doi-asserted-by":"crossref","first-page":"e213863","DOI":"10.1212\/WNL.0000000000213863","article-title":"Meta-analysis of randomized controlled trials on IV thrombolysis in patients with minor acute ischemic stroke","volume":"105","author":"M F Doheim","year":"2025","journal-title":"Neurology"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(26)00757-9","article-title":"Ticagrelor with aspirin dual antiplatelet therapy combined with intravenous thrombolysis in patients with ischaemic stroke in China (TAPIS): a multicentre, double-blind, randomised controlled trial","volume":"407","author":"A Wang","year":"2026","journal-title":"Lancet"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/S0140-6736(26)00820-2","article-title":"TAPIS: a positive trial in a defined phenotype","volume":"407","author":"B K Menon","year":"2026","journal-title":"Lancet"},{"issue":"26","key":"ref61","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2309137","article-title":"Dual antiplatelet treatment up to 72 hours after ischemic stroke","volume":"389","author":"Y Gao","year":"2023","journal-title":"N Engl J Med"},{"issue":"17","key":"ref62","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1001\/jama.2025.2033","article-title":"Long-term risk of stroke after transient ischemic attack or minor stroke: a systematic review and meta-analysis","volume":"333","author":"F Khan","year":"2025","journal-title":"JAMA"},{"issue":"10","key":"ref63","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1161\/STROKEAHA.120.031755","article-title":"Balancing benefits and risks of long-term antiplatelet therapy in noncardioembolic transient ischemic attack or stroke","volume":"52","author":"N A Hilkens","year":"2021","journal-title":"Stroke"},{"issue":"05","key":"ref64","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jamainternmed.2022.0323","article-title":"Evaluation of evidence-based dual antiplatelet therapy for secondary prevention in US patients with acute ischemic stroke","volume":"182","author":"Y Xian","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"9065","key":"ref65","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","article-title":"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke","volume":"349","author":"International Stroke Trial Collaborative Group","year":"1997","journal-title":"Lancet"},{"issue":"9523","key":"ref66","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","article-title":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial","volume":"367","author":"P H Halkes","year":"2006","journal-title":"Lancet"},{"issue":"20","key":"ref67","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMoa011258","article-title":"A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke","volume":"345","author":"J P Mohr","year":"2001","journal-title":"N Engl J Med"},{"issue":"06","key":"ref68","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"C Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"ref69","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41569-025-01144-z","article-title":"Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism","volume":"22","author":"D Capodanno","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"A Shoamanesh","year":"2022","journal-title":"Lancet"},{"issue":"01","key":"ref71","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","article-title":"Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"23","author":"M Sharma","year":"2024","journal-title":"Lancet Neurol"},{"issue":"15","key":"ref72","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2513880","article-title":"Asundexian for secondary stroke prevention","volume":"394","author":"M Sharma","year":"2026","journal-title":"N Engl J Med"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2952-7857.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:12:09Z","timestamp":1790377929000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2952-7857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":72,"URL":"https:\/\/doi.org\/10.1055\/a-2952-7857","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,9]]},"published":{"date-parts":[[2026,9,9]]}}}